Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04657991 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
A Phase 3 study of Melanoma, sponsored by Pfizer.
- Active
- Registry status
- Phase 3
- Development phase
- 257
- Enrollment target
- 20
- Study locations
NCT04657991 is a Phase 3 study of Melanoma that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 257 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT04657991, a Phase 3 study of Melanoma, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 257 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that: * is advanced or metastatic (spread to other parts of the body); * has a certain type of abnormal gene called "BRAF"; and * has not received prior treatment. All participants in this study will receive pembrolizumab at the study clinic once every 3 weeks as an intravenous (IV) infusion (given directly into a vein). In addition, half of the participants will take encorafenib and binimetinib orally (by mouth) at home every day. Participants may receive pembrolizumab for up to two years. Those participants taking encorafenib and binimetinib can continue until their melanoma is no longer responding. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Binimetinib
- DRUG Encorafenib
Study Locations (20)
Kansas
- The University of Kansas Clinical Research Center - Fairway
- University of Kansas Medical Center Research Institute - Kansas City
- The University of Kansas Cancer Center - Overland Park - Overland Park
- KU Eye Center - Prairie Village
- The University of Kansas Cancer Center - Investigational Drug Services - Westwood
- The University of Kansas Cancer Center - Westwood
Florida
- AdventHealth Hematology and Oncology - Orlando
- AdventHealth Orlando Infusion Center - Orlando
- AdventHealth Orlando, Investigational Drug Services - Orlando
- AdventHealth Orlando - Orlando
Tennessee
- University of Tennessee Medical Center - Knoxville
- Sarah Cannon Research Institute - Nashville
- Tennessee Oncology, PLLC - Nashville
Massachusetts
- Massachusetts General Hospital - Boston
- Ophthalmic Consultants of Boston Inc (OCB) - Boston
Ohio
- University of Cincinnati Medical Center - Cincinnati
- University of Cincinnati Medical Center - West Chester
Buenos Aires
- Instituto Alexander Fleming - CABA
Río Negro Province
- Clinica Viedma S. A - Viedma
Other
- Medizinische Universität Graz - Graz
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04657991
The ClinicalTrials.gov registry entry for NCT04657991 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 257 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (64% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04657991 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Kansas, Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04657991 about?
NCT04657991 is a clinical study titled "A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma". The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that: * is advanced or metastatic (spread to other parts of the body); * has a certain type of abnormal gene called "BRAF"; and...
What is the current status of trial NCT04657991?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 257 participants. The study started on 2021-01-15. Estimated completion is 2026-08-31.
What conditions does trial NCT04657991 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT04657991?
The interventions under investigation include: Pembrolizumab (DRUG), Binimetinib (DRUG), Encorafenib (DRUG).
Who is sponsoring clinical trial NCT04657991?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04657991 being conducted?
This trial has 20 study locations across Florida, Kansas, Massachusetts, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RECRUITING · Phase 3
-
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RECRUITING · Phase 3
-
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
ACTIVE NOT RECRUITING · Phase 3
-
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.